338 related articles for article (PubMed ID: 27378628)
1. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
[TBL] [Abstract][Full Text] [Related]
2. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
3. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
4. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
[TBL] [Abstract][Full Text] [Related]
5. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Bitanihirwe BK; Meerang M; Friess M; Soltermann A; Frischknecht L; Thies S; Felley-Bosco E; Tsao MS; Allo G; de Perrot M; Seifert B; Moch H; Stahel R; Weder W; Opitz I
J Thorac Oncol; 2014 Feb; 9(2):239-47. PubMed ID: 24419422
[TBL] [Abstract][Full Text] [Related]
6. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.
Opitz I; Friess M; Kestenholz P; Schneiter D; Frauenfelder T; Nguyen-Kim TD; Seifert B; Hoda MA; Klepetko W; Stahel RA; Weder W
J Thorac Oncol; 2015 Nov; 10(11):1634-41. PubMed ID: 26317916
[TBL] [Abstract][Full Text] [Related]
7. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation.
Yokoyama T; Osada H; Murakami H; Tatematsu Y; Taniguchi T; Kondo Y; Yatabe Y; Hasegawa Y; Shimokata K; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2008 Nov; 29(11):2139-46. PubMed ID: 18725387
[TBL] [Abstract][Full Text] [Related]
8. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
Kirschner MB; Cheng YY; Armstrong NJ; Lin RC; Kao SC; Linton A; Klebe S; McCaughan BC; van Zandwijk N; Reid G
Mol Oncol; 2015 Mar; 9(3):715-26. PubMed ID: 25497279
[TBL] [Abstract][Full Text] [Related]
9. Role of hedgehog signaling in malignant pleural mesothelioma.
Shi Y; Moura U; Opitz I; Soltermann A; Rehrauer H; Thies S; Weder W; Stahel RA; Felley-Bosco E
Clin Cancer Res; 2012 Sep; 18(17):4646-56. PubMed ID: 22733539
[TBL] [Abstract][Full Text] [Related]
10. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
Kang Y; Ding M; Tian G; Guo H; Wan Y; Yao Z; Li B; Lin D
Oncol Rep; 2013 Jul; 30(1):313-9. PubMed ID: 23624653
[TBL] [Abstract][Full Text] [Related]
12. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
13. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
14. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Sato T; Sekido Y
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Soldera SV; Kavanagh J; Pintilie M; Leighl NB; de Perrot M; Cho J; Hope A; Feld R; Bradbury PA
Oncologist; 2019 Jul; 24(7):e510-e517. PubMed ID: 30478189
[TBL] [Abstract][Full Text] [Related]
16. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
18. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
[TBL] [Abstract][Full Text] [Related]
19. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
[No Abstract] [Full Text] [Related]
20. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
